Difluorocarbene radiosynthesis
US-2024383827-A1 · Nov 21, 2024 · US
Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation
US9364448B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9364448-B2 |
| Application number | US-201414471142-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 28, 2014 |
| Priority date | Feb 26, 2010 |
| Publication date | Jun 14, 2016 |
| Grant date | Jun 14, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of increasing visually discernible pigmentation in an iris of a subject, the method comprising administering to the subject a pharmaceutical composition comprising (a) 2-(-2-nitro-4 trifluoromethylbenzoyl)-1,3 cyclohexanedione (NTBC) or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and (b) a pharmaceutically and physiologically acceptable carrier in an amount effective to increase the number of pigmented melanosomes in the ir…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- A61K31/122Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9364448B2 cover?
- A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutic…
- Who is the assignee on this patent?
- Us Health
- What technology area does this patent fall under?
- Primary CPC classification A61K31/122. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).